A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 70 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 8th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 5th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 783 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 25th largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 51 in phase 3, and was the 6th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
Drug: Tirzepatide
Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.
Drug: Tirzepatide
Participants received weekly doses of placebo SC for 52 weeks.
Other: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Percent Change From Randomization in Body Weight at Week 88
Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Percent Change From Randomization in Body Weight at Week 64
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 64
Change From Randomization in Body Weight
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Waist Circumference
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Body Mass Index (BMI)
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Fasting Glucose
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Hemoglobin A1c (HbA1c)
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Percent Change From Randomization in Fasting Insulin
LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Percent Change From Randomization in Lipid Parameters (Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Very Low Density Lipoprotein (VLDL) Cholesterol, Triglycerides, Free Fatty Acids (FFA))
LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
LS mean change was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
Time frame: Randomization (Week 36), Week 88
Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period
Percentage of Participants Who Maintain at least 80% of the Body Weight Lost During the Open-Label Lead-In Period was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.
Time frame: Week 88
Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline
Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction from baseline was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.
Time frame: Baseline (Week 0) to Week 88
Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period
Time to first occurrence of participants returning to \>95% baseline weight for those who lost ≥5% during the open-label lead-in period.
Time frame: Randomization (Week 36) to Week 88
Change From Baseline in BMI
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + BMI at randomization (kg/m\^2) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in Body Weight
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Percent Change From Baseline in Body Weight
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in Waist Circumference
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in Fasting Glucose
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in HbA1c
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Percent Change From Baseline in Fasting Insulin
LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Percent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)
LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in SBP, DBP
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with baseline + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
Time frame: Baseline (Week 0), Week 88
| Milestone | Tirzepatide (lead-in) | Placebo | Tirzepatide MTD |
|---|---|---|---|
| Started | 783 | 0 | 0 |
| Received at least 1 dose of study drug | 782 | 0 | 0 |
| Completed 36-weeks of treatment (i.e., reaching and tolerating the mtd at week 36) | 670 | 0 | 0 |
| Completed | 671 | 0 | 0 |
| Not completed | 112 | 0 | 0 |
| Withdrew: Adverse event | 50 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 14 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 10 | 0 | 0 |
| Withdrew: Withdrawal by subject | 32 | 0 | 0 |
| Withdrew: Covid-19 | 1 | 0 | 0 |
| Withdrew: Other - as reported by the investigator | 2 | 0 | 0 |
| Milestone | Tirzepatide (lead-in) | Placebo | Tirzepatide MTD |
|---|---|---|---|
| Started | 0 | 335 | 335 |
| Received at least 1 dose of study drug | 0 | 335 | 335 |
| Completed | 0 | 290 | 310 |
| Not completed | 0 | 45 | 25 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 10 | 8 |
| Withdrew: Pregnancy | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 22 | 13 |
| Withdrew: Protocol deviation | 0 | 1 | 2 |
| Withdrew: Other - as reported by the investigator | 0 | 8 | 0 |
| Withdrew: Perceived excessive weight loss | 0 | 1 | 0 |
Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Percent Change From Randomization in Body Weight at Week 88 | 14.8 ± 0.53 | -6.7 ± 0.52 |
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Percent Change From Randomization in Body Weight at Week 64 | 9.9 ± 0.38 | -6.0 ± 0.37 |
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
| kilogram (kg) | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Body Weight | 11.9 ± 0.43 | -5.7 ± 0.42 |
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| centimetre (cm) | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Waist Circumference | 8.3 ± 0.44 | -4.6 ± 0.43 |
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
| kilogram per square metre (kg/m^2) | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Body Mass Index (BMI) | 4.3 ± 0.16 | -2.1 ± 0.15 |
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| milligrams per deciliter (mg/dL) | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Fasting Glucose | 7.74 ± 0.548 | -0.90 ± 0.528 |
LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percentage of HbA1c | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Hemoglobin A1c (HbA1c) | 0.25 ± 0.017 | -0.08 ± 0.017 |
LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Percent Change From Randomization in Fasting Insulin | 23.3 ± 4.37 | -15.4 ± 2.88 |
LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Total Cholesterol | 8.30 ± 0.943 | 2.29 ± 0.852 |
| LDL Cholesterol | 3.43 ± 1.368 | -3.36 ± 1.218 |
| HDL Cholesterol | 14.6 ± 1.06 | 18.3 ± 1.05 |
| VLDL Cholesterol | 14.7 ± 2.32 | -7.8 ± 1.77 |
| Triglycerides | 15.6 ± 2.39 | -8.2 ± 1.81 |
| FFA | -2.9 ± 2.98 | -13.4 ± 2.54 |
LS mean change was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| millimetre of mercury (mmHg) | Placebo | Tirzepatide MTD |
|---|---|---|
| SBP | 8.4 ± 0.64 | 2.1 ± 0.61 |
| DBP | 3.2 ± 0.44 | -0.4 ± 0.42 |
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
| T-score | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score | -1.8 ± 0.32 | 0.8 ± 0.31 |
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
| score on a scale | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score | -5.0 ± 0.95 | 4.4 ± 0.91 |
Percentage of Participants Who Maintain at least 80% of the Body Weight Lost During the Open-Label Lead-In Period was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.
| percentage of participants | Placebo | Tirzepatide MTD |
|---|---|---|
| Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period | 13.50 | 93.37 |
Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction from baseline was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.
| percentage of participants | Placebo | Tirzepatide MTD |
|---|---|---|
| ≥5% body weight reduction from baseline | 69.00 | 98.49 |
| ≥10% body weight reduction from baseline | 44.38 | 93.98 |
| ≥15% body weight reduction from baseline | 24.01 | 87.05 |
| ≥20% body weight reduction from baseline | 11.55 | 72.59 |
Time to first occurrence of participants returning to \>95% baseline weight for those who lost ≥5% during the open-label lead-in period.
| weeks | Placebo | Tirzepatide MTD |
|---|---|---|
| Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period | NA (NA to NA) | NA (NA to NA) |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + BMI at randomization (kg/m\^2) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| kg/m^2 | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in BMI | -3.6 ± 0.16 | -10.0 ± 0.15 |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| kg | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in Body Weight | -10.0 ± 0.43 | -27.6 ± 0.42 |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Percent Change From Baseline in Body Weight | -9.5 ± 0.40 | -26.0 ± 0.39 |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| cm | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in Waist Circumference | -9.1 ± 0.53 | -22.8 ± 0.52 |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| mg/dL | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in Fasting Glucose | -1.72 ± 0.543 | -10.63 ± 0.522 |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percentage of HbA1c | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in HbA1c | -0.22 ± 0.018 | -0.57 ± 0.017 |
LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Percent Change From Baseline in Fasting Insulin | -29.8 ± 2.52 | -54.1 ± 1.57 |
LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| percent change | Placebo | Tirzepatide MTD |
|---|---|---|
| Total Cholesterol | 2.16 ± 0.919 | -5.01 ± 0.817 |
| LDL Cholesterol | 2.62 ± 1.371 | -5.21 ± 1.207 |
| HDL Cholesterol | 9.44 ± 1.093 | 12.29 ± 1.071 |
| VLDL Cholesterol | -15.6 ± 1.82 | -32.6 ± 1.37 |
| Triglycerides | -15.3 ± 1.84 | -33.3 ± 1.38 |
| FFA | -9.69 ± 2.811 | -20.38 ± 2.360 |
LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.
| mmHg | Placebo | Tirzepatide MTD |
|---|---|---|
| SBP | -2.4 ± 0.66 | -9.3 ± 0.63 |
| DBP | -1.7 ± 0.46 | -5.5 ± 0.44 |
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
| T-score | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score | 3.7 ± 0.36 | 6.3 ± 0.34 |
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with baseline + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.
| score on a scale | Placebo | Tirzepatide MTD |
|---|---|---|
| Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score | 16.7 ± 1.01 | 26.0 ± 0.97 |
Collected over Week 0 to 36 for the open-label lead-in period arm, Week 36 to 92 for the double-blind study period arms.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide (lead-in) | 1/782 (0.1%) | 16/782 (2%) | 559/782 (71.5%) |
| Placebo | 1/335 (0.3%) | 10/335 (3%) | 100/335 (29.9%) |
| Tirzepatide MTD | 1/335 (0.3%) | 10/335 (3%) | 124/335 (37%) |
| Event | Tirzepatide (lead-in) | Placebo | Tirzepatide MTD |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 4/782 | 3/335 | 0/335 |
| CellulitisInfections and infestations | 0/782 | 0/335 | 2/335 |
| Acute myocardial infarctionCardiac disorders | 0/782 | 0/335 | 1/335 |
| Cardiac failure congestiveCardiac disorders | 0/782 | 0/335 | 1/335 |
| Abdominal painGastrointestinal disorders | 0/782 | 0/335 | 1/335 |
| Intestinal obstructionGastrointestinal disorders | 0/782 | 1/335 | 1/335 |
| NauseaGastrointestinal disorders | 0/782 | 0/335 | 1/335 |
| Peptic ulcerGastrointestinal disorders | 0/782 | 0/335 | 1/335 |
| Small intestinal obstructionGastrointestinal disorders | 0/782 | 0/335 | 1/335 |
| VomitingGastrointestinal disorders | 0/782 | 0/335 | 1/335 |
| Event | Tirzepatide (lead-in) | Placebo | Tirzepatide MTD |
|---|---|---|---|
| NauseaGastrointestinal disorders | 278/782 | 9/335 | 27/335 |
| DiarrhoeaGastrointestinal disorders | 165/782 | 16/335 | 36/335 |
| ConstipationGastrointestinal disorders | 162/782 | 8/335 | 12/335 |
| VomitingGastrointestinal disorders | 128/782 | 4/335 | 18/335 |
| Covid-19Infections and infestations | 82/782 | 50/335 | 47/335 |
| Decreased appetiteMetabolism and nutrition disorders | 74/782 | 4/335 | 7/335 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 69/782 | 1/335 | 4/335 |
| Injection site reactionGeneral disorders | 64/782 | 2/335 | 7/335 |
| DyspepsiaGastrointestinal disorders | 63/782 | 1/335 | 1/335 |
| HeadacheNervous system disorders | 56/782 | 10/335 | 5/335 |
All randomized participants.
| Age, Continuous(years) | Placebo | Tirzepatide MTD | Total |
|---|---|---|---|
| Mean | 47.15 ± 12.38 | 48.27 ± 12.79 | 47.71 ± 12.59 |
| Sex: Female, Male(Participants) | Placebo | Tirzepatide MTD | Total |
|---|---|---|---|
| Female | 237 | 236 | 473 |
| Male | 98 | 99 | 197 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tirzepatide MTD | Total |
|---|---|---|---|
| Hispanic or Latino | 155 | 141 | 296 |
| Not Hispanic or Latino | 180 | 193 | 373 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Tirzepatide MTD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 22 | 26 | 48 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 36 | 39 | 75 |
| White | 273 | 264 | 537 |
| More than one race | 3 | 5 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Tirzepatide MTD | Total |
|---|---|---|---|
| Argentina | 56 | 55 | 111 |
| Brazil | 46 | 43 | 89 |
| Taiwan | 17 | 21 | 38 |
| United States | 216 | 216 | 432 |
| Body weight(kilogram (kg)) | Placebo | Tirzepatide MTD | Total |
|---|---|---|---|
| Mean | 107.79 ± 23.66 | 106.82 ± 20.94 | 107.3 ± 22.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2021 to primary completion in Apr 2023, 24 months.
Results were first posted in May 2024, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide